FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2406136546> ?p ?o ?g. }

• W2406136546 abstract "BACKGROUND: CNS progression results in frequent treatment failure for ALK+ NSCLC patients receiving the ALK inhibitor crizotinib. CNS efficacy is important in assessing new ALK inhibitors and accurate assessment of response/progression is vital in determining treatment efficacy. Data from two phase II studies in pre-treated ALK+ NSCLC were pooled to examine the CNS efficacy of the highly selective ALK inhibitor alectinib, using both Response Evaluation Criteria in Solid Tumors (RECIST) and Response Assessment in Neuro-Oncology (RANO) criteria to evaluate brain metastases. METHODS: The phase II, single-arm, multicenter studies both enrolled ALK+ NSCLC patients aged ≥18 years who had previously received crizotinib. NP28761 was conducted in North America only (NCT01871805); NP28673 was a global study (NCT01801111). All patients in both studies received 600mg oral alectinib twice daily. Patients underwent imaging at baseline to assess CNS metastases and CNS response was determined by an independent review committee (IRC) according to RECIST v1.1 or RANO criteria. RESULTS: Fifty-one patients had baseline measurable CNS disease by IRC according to RECIST v1.1, and 43 according to RANO criteria. The CNS objective response rate (ORR) was 60.8% by RECIST (95% CI 46.1–74.2; 9 CNS complete responses [CRs]; CNS disease control rate [DCR] 90.2%) and 51.2% by RANO (95% CI 35.5–66.7; 5 CNS CRs; CNS DCR 83.7%). Responses by RECIST included both confirmed and unconfirmed responses; those by RANO had to be confirmed. Median duration of CNS response was 9.1 months with RECIST (95% CI 5.8–NE; 39% of responders with event) and 9.1 months with RANO (95% CI 7.4–NE; 36% of responders with event). CONCLUSION: Alectinib demonstrated promising and durable efficacy in the CNS for ALK+ NSCLC patients previously treated with crizotinib, regardless of the assessment criteria used. Updated results from a later cut-off, plus correlative data and additional analyses, will be presented." @default.
• W2406136546 created "2016-06-24" @default.
• W2406136546 creator A5019037704 @default.
• W2406136546 creator A5020504047 @default.
• W2406136546 creator A5025836672 @default.
• W2406136546 creator A5040616756 @default.
• W2406136546 creator A5040900859 @default.
• W2406136546 creator A5048952656 @default.
• W2406136546 creator A5055074037 @default.
• W2406136546 creator A5062173452 @default.
• W2406136546 creator A5080311196 @default.
• W2406136546 creator A5082517668 @default.
• W2406136546 creator A5083698345 @default.
• W2406136546 creator A5087923582 @default.
• W2406136546 date "2015-11-01" @default.
• W2406136546 modified "2023-09-23" @default.
• W2406136546 title "BMET-18ASSESSING CENTRAL NERVOUS SYSTEM (CNS) RESPONSE TO ALECTINIB IN TWO PHASE II STUDIES OF PRE-TREATED ALK+ NON-SMALL CELL LUNG CANCER (NSCLC): RECIST VERSUS RANO CRITERIA" @default.
• W2406136546 doi "https://doi.org/10.1093/neuonc/nov208.18" @default.
• W2406136546 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4638620" @default.
• W2406136546 hasPublicationYear "2015" @default.
• W2406136546 type Work @default.
• W2406136546 sameAs 2406136546 @default.
• W2406136546 citedByCount "1" @default.
• W2406136546 countsByYear W24061365462016 @default.
• W2406136546 crossrefType "journal-article" @default.
• W2406136546 hasAuthorship W2406136546A5019037704 @default.
• W2406136546 hasAuthorship W2406136546A5020504047 @default.
• W2406136546 hasAuthorship W2406136546A5025836672 @default.
• W2406136546 hasAuthorship W2406136546A5040616756 @default.
• W2406136546 hasAuthorship W2406136546A5040900859 @default.
• W2406136546 hasAuthorship W2406136546A5048952656 @default.
• W2406136546 hasAuthorship W2406136546A5055074037 @default.
• W2406136546 hasAuthorship W2406136546A5062173452 @default.
• W2406136546 hasAuthorship W2406136546A5080311196 @default.
• W2406136546 hasAuthorship W2406136546A5082517668 @default.
• W2406136546 hasAuthorship W2406136546A5083698345 @default.
• W2406136546 hasAuthorship W2406136546A5087923582 @default.
• W2406136546 hasBestOaLocation W24061365461 @default.
• W2406136546 hasConcept C126322002 @default.
• W2406136546 hasConcept C143998085 @default.
• W2406136546 hasConcept C2776232967 @default.
• W2406136546 hasConcept C2776256026 @default.
• W2406136546 hasConcept C2778347629 @default.
• W2406136546 hasConcept C2778822529 @default.
• W2406136546 hasConcept C2779134260 @default.
• W2406136546 hasConcept C2779220645 @default.
• W2406136546 hasConcept C2779422266 @default.
• W2406136546 hasConcept C2779750558 @default.
• W2406136546 hasConcept C2779984678 @default.
• W2406136546 hasConcept C31760486 @default.
• W2406136546 hasConcept C535046627 @default.
• W2406136546 hasConcept C71924100 @default.
• W2406136546 hasConceptScore W2406136546C126322002 @default.
• W2406136546 hasConceptScore W2406136546C143998085 @default.
• W2406136546 hasConceptScore W2406136546C2776232967 @default.
• W2406136546 hasConceptScore W2406136546C2776256026 @default.
• W2406136546 hasConceptScore W2406136546C2778347629 @default.
• W2406136546 hasConceptScore W2406136546C2778822529 @default.
• W2406136546 hasConceptScore W2406136546C2779134260 @default.
• W2406136546 hasConceptScore W2406136546C2779220645 @default.
• W2406136546 hasConceptScore W2406136546C2779422266 @default.
• W2406136546 hasConceptScore W2406136546C2779750558 @default.
• W2406136546 hasConceptScore W2406136546C2779984678 @default.
• W2406136546 hasConceptScore W2406136546C31760486 @default.
• W2406136546 hasConceptScore W2406136546C535046627 @default.
• W2406136546 hasConceptScore W2406136546C71924100 @default.
• W2406136546 hasLocation W24061365461 @default.
• W2406136546 hasLocation W24061365462 @default.
• W2406136546 hasOpenAccess W2406136546 @default.
• W2406136546 hasPrimaryLocation W24061365461 @default.
• W2406136546 isParatext "false" @default.
• W2406136546 isRetracted "false" @default.
• W2406136546 magId "2406136546" @default.
• W2406136546 workType "article" @default.